BACKGROUND: Patients with recent coronary artery bypass graft (CABG) surgery are at risk for early graft failure, which is associated with a risk of myocardial infarction and death. In the COMPASS (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS) trial, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced the primary major adverse cardiovascular events (MACE) outcome of cardiovascular death, stroke, or myocardial infarction. Rivaroxaban 5 mg twice daily alone did not significantly reduce MACE. OBJECTIVES: This pre-planned substudy sought to determine whether the COMPASS treatments are more effective than aspirin alone for preventing graft failure and MACE after CABG surgery. METHODS: The substudy randomized 1,448 COMPASS trial patients 4 to 14 days after CABG surgery to receive the combination of rivaroxaban plus aspirin, rivaroxaban alone, or aspirin alone. The primary outcome was graft failure, diagnosed by computed tomography angiogram 1 year after surgery. RESULTS: The combination of rivaroxaban and aspirin and the regimen of rivaroxaban alone did not reduce the graft failure rates compared with aspirin alone (combination vs. aspirin: 113 [9.1%] vs. 91 [8.0%] failed grafts; odds ratio [OR]: 1.13; 95% confidence interval [CI]: 0.82 to 1.57; p = 0.45; rivaroxaban alone vs. aspirin: 92 [7.8%] vs. 92 [8.0%] failed grafts; OR: 0.95; 95% CI: 0.67 to 1.33; p = 0.75). Compared with aspirin, the combination was associated with fewer MACE (12 [2.4%] vs. 16 [3.5%]; hazard ratio [HR]: 0.69; 95% CI: 0.33 to 1.47; p = 0.34), whereas rivaroxaban alone was not (16 [3.3%] vs. 16 [3.5%]; HR: 0.99, CI: 0.50 to 1.99; p = 0.98). There was no fatal bleeding or tamponade within 30 days of randomization. CONCLUSIONS: The combination of rivaroxaban 2.5 mg twice daily plus aspirin or rivaroxaban 5 mg twice daily alone compared with aspirin alone did not reduce graft failure in patients with recent CABG surgery, but the combination of rivaroxaban 2.5 mg twice daily plus aspirin was associated with similar reductions in MACE, as observed in the larger COMPASS trial. (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS [COMPASS]; NCT01776424).

Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston Massachusetts

Cardiocenter University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague Czech Republic

Centre for Cardiovascular Science University of Edinburgh Edinburgh United Kingdom

FuWai Hospital Beijing China

Institut Universitaire de Cardiologie et de Pnemologie de Québec Quebec City Quebec Canada

Population Health Research Institute McMaster University Hamilton Ontario Canada

Population Health Research Institute McMaster University Hamilton Ontario Canada; CADENCE Research Group Hamilton Health Sciences Hamilton Ontario Canada; Department of Surgery McMaster University Hamilton Ontario Canada; Department of Health Research Methods Evidence and Impact McMaster University Hamilton Ontario Canada

Population Health Research Institute McMaster University Hamilton Ontario Canada; Department of Health Research Methods Evidence and Impact McMaster University Hamilton Ontario Canada; Department of Medicine McMaster University Hamilton Ontario Canada

Population Health Research Institute McMaster University Hamilton Ontario Canada; Department of Medicine McMaster University Hamilton Ontario Canada

Quebec Heart and Lung University Institute Laval University Quebec City Quebec Canada

Shanghai Chest Hospital Affiliated with Shanghai Jiao Tong University Shanghai China

University of Washington Medical Center Seattle Washington

J Am Coll Cardiol. 2019 Jan 22;73(2):131-133. doi: 10.1016/j.jacc.2018.10.049. PubMed

J Am Coll Cardiol. 2019 May 14;73(18):2359-2360. doi: 10.1016/j.jacc.2019.01.075. PubMed

J Am Coll Cardiol. 2019 May 14;73(18):2360. doi: 10.1016/j.jacc.2019.03.022. PubMed

References provided by Crossref.org

Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial

See more in PubMed

ClinicalTrials.gov
NCT01776424